Related references
Note: Only part of the references are listed.Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study
Mette Deleuran et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2020)
Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS)
A. Wollenberg et al.
BRITISH JOURNAL OF DERMATOLOGY (2020)
Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus
Jonathan Silverberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2020)
Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb
Andreas Wollenberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis
Emma Guttman-Yassky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
GBR 830, an anti-OX40, improves skin gene signatures and clinical scores in patients with atopic dermatitis
Emma Guttman-Yassky et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Conjunctivitis in dupilumab clinical trials
B. Akinlade et al.
BRITISH JOURNAL OF DERMATOLOGY (2019)
Scratching Counteracts IL-13 Signaling by Upregulating the Decoy Receptor IL-13Rα2 in Keratinocytes
Dugarmaa Ulzii et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Omalizumab for atopic dermatitis: evidence for and against its use
Jesper G. Holm et al.
GIORNALE ITALIANO DI DERMATOLOGIA E VENEREOLOGIA (2019)
IL-4 Augments IL-31/IL-31 Receptor Alpha Interaction Leading to Enhanced Ccl 17 and Ccl 22 Production in Dendritic Cells: Implications for Atopic Dermatitis
Sho Miake et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2019)
Atopic dermatitis endotypes and implications for targeted therapeutics
Tali Czarnowicki et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2019)
Atopic Dermatitis Is an IL-13-Dominant Disease with Greater Molecular Heterogeneity Compared to Psoriasis
Lam C. Tsoi et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2019)
Tezepelumab, an anti-thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial
Eric L. Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2019)
Interleukin-1 receptor antagonist levels predict favorable outcome after bermekimab, a first-in-class true human interleukin-1 alpha antibody, in a phase III randomized study of advanced colorectal cancer
Razelle Kurzrock et al.
ONCOIMMUNOLOGY (2019)
Epidemiology of atopic dermatitis in adults: Results from an international survey
S. Barbarot et al.
ALLERGY (2018)
Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis
Chisa Nakashima et al.
EXPERIMENTAL DERMATOLOGY (2018)
Neutralization of IL-17C Reduces Skin Inflammation in Mouse Models of Psoriasis and Atopic Dermatitis
Nick Vandeghinste et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2018)
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial
Emma Guttman-Yassky et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE)
Eric L. Simpson et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2018)
Conjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment
Andreas Wollenberg et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY-IN PRACTICE (2018)
New Cytokines in the Pathogenesis of Atopic Dermatitis-New Therapeutic Targets
Jolanta Klonowska et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis
Saakshi Khattri et al.
EXPERIMENTAL DERMATOLOGY (2017)
The Role of Interleukin-1 in Inflammatory and Malignant Human Skin Diseases and the Rationale for Targeting Interleukin-1 Alpha
Mayassa J. Bou-Dargham et al.
MEDICINAL RESEARCH REVIEWS (2017)
IL-17 for therapy
Florian C. Kurschus et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2017)
Expression of IL-22 in the Skin Causes Th2-Biased Immunity, Epidermal Barrier Dysfunction, and Pruritus via Stimulating Epithelial Th2 Cytokines and the GRP Pathway
Hongfei Lou et al.
JOURNAL OF IMMUNOLOGY (2017)
Increasing Comorbidities Suggest that Atopic Dermatitis Is a Systemic Disorder
Patrick M. Brunner et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
An Integrated Model of Atopic Dermatitis Biomarkers Highlights the Systemic Nature of the Disease
Benjamin Ungar et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2017)
Structural Characterisation Reveals Mechanism of IL-13-Neutralising Monoclonal Antibody Tralokinumab as Inhibition of Binding to IL-13Rα1 and IL-13Rα2
B. Popovic et al.
JOURNAL OF MOLECULAR BIOLOGY (2017)
Phase I randomized study of KHK4083, an anti-OX40 monoclonal antibody, in patients with mild to moderate plaque psoriasis
K. A. Papp et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2017)
Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial
Andrew Blauvelt et al.
LANCET (2017)
Atopic Dermatitis Anti-IgE Paediatric Trial (ADAPT): the role of anti-IgE in severe paediatric eczema: study protocol for a randomised controlled trial
Susan Chan et al.
TRIALS (2017)
Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study
H. Saeki et al.
BRITISH JOURNAL OF DERMATOLOGY (2017)
Atopic dermatitis treatment: Current state of the art and emerging therapies
Jonathan I. Silverberg
ALLERGY AND ASTHMA PROCEEDINGS (2017)
The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis
Jonathan I. Silverberg et al.
DERMATOLOGIC CLINICS (2017)
Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis
E. L. Simpson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Modelling atopic dermatitis during the morphogenetic process involved in reconstruction of a human epidermis
E. De Vuyst et al.
CURRENT RESEARCH IN TRANSLATIONAL MEDICINE (2016)
Molecular Mechanisms of Cutaneous Inflammatory Disorder: Atopic Dermatitis
Jung Eun Kim et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2016)
Serum interleukin 17, interleukin 23, and interleukin 10 values in children with atopic eczema/dermatitis syndrome (AEDS): Association with clinical severity and phenotype
Salvatore Leonardi et al.
ALLERGY AND ASTHMA PROCEEDINGS (2015)
IL-33 impacts on the skin barrier by down-regulating the expression of filaggrin
Jenny Seltmann et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Alopecia areata profiling shows TH1, TH2, and IL-23 cytokine activation without parallel TH17/TH22 skewing
Mayte Suarez-Farinas et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization
Shinji Noda et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2015)
Increased efficacy of omalizumab in atopic dermatitis patients with wild-type filaggrin status and higher serum levels of phosphatidylcholines
M. Hotze et al.
ALLERGY (2014)
IL-33 Promotes the Induction and Maintenance of Th2 Immune Responses by Enhancing the Function of OX40 Ligand
Naoko Murakami-Satsutani et al.
ALLERGOLOGY INTERNATIONAL (2014)
The Epithelial Cell-Derived Atopic Dermatitis Cytokine TSLP Activates Neurons to Induce Itch
Sarah R. Wilson et al.
CELL (2013)
Epidermal TSLP: a trigger factor for pathogenesis of atopic dermatitis
Arup K. Indra
EXPERT REVIEW OF PROTEOMICS (2013)
A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis
Maryam Salimi et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2013)
Structural Basis of Signaling Blockade by Anti-IL-13 Antibody Lebrikizumab
Mark Ultsch et al.
JOURNAL OF MOLECULAR BIOLOGY (2013)
OX40 ligand and OX40 are increased in atopic dermatitis lesions but do not correlate with clinical severity
T. Ilves et al.
JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY (2013)
The Th17/IL-23 Axis and Natural Immunity in Psoriatic Arthritis
Shinji Maeda et al.
INTERNATIONAL JOURNAL OF RHEUMATOLOGY (2012)
IL-13 Antibodies Influence IL-13 Clearance in Humans by Modulating Scavenger Activity of IL-13Rα2
Marion T. Kasaian et al.
JOURNAL OF IMMUNOLOGY (2011)
IL-17C regulates the innate immune function of epithelial cells in an autocrine manner
Vladimir Ramirez-Carrozzi et al.
NATURE IMMUNOLOGY (2011)
Transgenic Expression of Interleukin-13 in the Skin Induces a Pruritic Dermatitis and Skin Remodeling
Tao Zheng et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2009)
The role of TNF superfamily members in T-cell function and diseases
Michael Croft
NATURE REVIEWS IMMUNOLOGY (2009)
Loricrin and involucrin expression is down-regulated by Th2 cytokines through STAT-6
Byung Eui Kim et al.
CLINICAL IMMUNOLOGY (2008)
IL-31: A new link between T cells and pruritus in atopic skin inflammation
E Sonkoly et al.
JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY (2006)
Treatment of recalcitrant atopic dermatitis with omalizumab
JE Lane et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2006)
Failure of omalizumab for treatment of severe adult atopic dermatitis
RA Krathen et al.
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY (2005)
Anti-IL-5 recombinant humanized monoclonal antibody (Mepolizumab) for the treatment of atopic dermatitis
JM Oldhoff et al.
ALLERGY (2005)
Enhanced interleukin (IL)-13 responses in mice lacking IL-13 receptor α 2
N Wood et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2003)
Share Paper
